ReviewPurinergic signalling2012
Perspectives of purinergic signaling in stem cell differentiation and tissue regeneration.
Review in Purinergic signalling, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 74 citations in OpenAlex.
- The purinergic signaling interfaces in breast cancer angiogenesis.Purinergic signalling · 2026Review
- Activating PIK3CA mutations in adipose-derived stem cells drive mutant-like phenotypes of wild-type cells in macrodactyly.Cell death & disease · 2025Article
- Purinergic receptors play a key role in shock wave-induced proliferation.Scientific reports · 2025Article
- Identification of purinergic system components in the venom of Bothrops mattogrossensis and the inhibitory effect of specioside extracted from Tabebuia aurea.Purinergic signalling · 2025Article
- Purinergic system in cancer stem cells.Purinergic signalling · 2025Review
- Regulation of GABAergic neurotransmission by purinergic receptors in brain physiology and disease.Purinergic signalling · 2025Review
- Role of Neurotransmitters in Steady State Hematopoiesis, Aging, and Leukemia.Stem cell reviews and reports · 2025Review
- Mesenchymal Stem Cells and Purinergic Signaling in Autism Spectrum Disorder: Bridging the Gap between Cell-Based Strategies and Neuro-Immune Modulation.Biomedicines · 2024Review
- ROS/MMP-9 mediated CS degradation in BMSC inhibits citric acid metabolism participating in the dual regulation of bone remodelling.Cell death discovery · 2024Article
- Purinergic Signaling and its Role in the Stem Cell Differentiation.Mini reviews in medicinal chemistry · 2024Review
- Adenosine metabolism by mesenchymal stromal cells isolated from different human tissues.Human cell · 2023Article
- Effects of Stromal Cell Conditioned Medium and Antipurinergic Treatment on Macrophage Phenotype.Tissue engineering. Part C, Methods · 2022Article
- UTP Regulates the Cardioprotective Action of Transplanted Stem Cells Derived From Mouse Cardiac Adipose Tissue.Frontiers in pharmacology · 2022Article
- UTP is a regulator of in vitro and in vivo angiogenic properties of cardiac adipose-derived stem cells.Purinergic signalling · 2021Article
- Pulmonary Sensory Receptors.Advances in anatomy, embryology, and cell biology · 2021Article
- Functional Exploration of the Pulmonary NEB ME.Advances in anatomy, embryology, and cell biology · 2021Article
- Adult mesenchymal stem cells: is there a role for purine receptors in their osteogenic differentiation?Purinergic signalling · 2020Review
- Immortalization of Mesenchymal Stromal Cells by TERT Affects Adenosine Metabolism and Impairs their Immunosuppressive Capacity.Stem cell reviews and reports · 2020Article
- The P2X7 Receptor in the Maintenance of Cancer Stem Cells, Chemoresistance and Metastasis.Stem cell reviews and reports · 2020Review
- P2X7 receptor signaling during adult hippocampal neurogenesis.Neural regeneration research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Replacement of lost or dysfunctional tissues by stem cells has recently raised many investigations on therapeutic applications. Purinergic signaling has been shown to regulate proliferation, differentiation, cell death, and successful engraftment of stem cells originated from diverse origins. Adenosine triphosphate release occurs in a controlled way by exocytosis, transporters, and lysosomes or in large amounts from damaged cells, which is then subsequently degraded into adenosine. Paracrine and autocrine mechanisms induced by immune responses present critical factors for the success of stem cell therapy. While P1 receptors generally exert beneficial effects including anti-inflammatory activity, P2 receptor-mediated actions depend on the subtype of stimulated receptors and localization of tissue repair. Pro-inflammatory actions and excitatory tissue damages mainly result from P2X7 receptor activation, while other purinergic receptor subtypes participate in proliferation and differentiation, thereby providing adequate niches for stem cell engraftment and novel mechanisms for cell therapy and endogenous tissue repair. Therapeutic applications based on regulation of purinergic signaling are foreseen for kidney and heart muscle regeneration, Clara-like cell replacement for pulmonary and bronchial epithelial cells as well as for induction of neurogenesis in case of neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.